Last reviewed · How we verify
Finacea
At a glance
| Generic name | Finacea |
|---|---|
| Also known as | Finacea® (azelaic acid) Gel, 15% (Intendis) |
| Sponsor | Actavis Inc. |
| Target | 3-oxo-5-alpha-steroid 4-dehydrogenase 2 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
- Acne vulgaris
- Rosacea
Common side effects
- Application site pain
- Application site pruritus
- Application site dryness
- Application site erythema
Serious adverse events
- Hypersensitivity
- Rash
- Worsening of asthma
- Hypopigmentation
- Eye and mucous membranes irritation
Key clinical trials
- Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (EARLY_PHASE1)
- Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation (PHASE1)
- Azelaic Acid 20% vs Hydroquinone 4% in Epidermal Melasma (NA)
- Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne (PHASE4)
- To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel (PHASE1)
- A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily (PHASE4)
- A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face (PHASE2)
- A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Finacea CI brief — competitive landscape report
- Finacea updates RSS · CI watch RSS
- Actavis Inc. portfolio CI